JP2018512401A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512401A5 JP2018512401A5 JP2017548089A JP2017548089A JP2018512401A5 JP 2018512401 A5 JP2018512401 A5 JP 2018512401A5 JP 2017548089 A JP2017548089 A JP 2017548089A JP 2017548089 A JP2017548089 A JP 2017548089A JP 2018512401 A5 JP2018512401 A5 JP 2018512401A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- seq
- tumor
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562132374P | 2015-03-12 | 2015-03-12 | |
| US62/132,374 | 2015-03-12 | ||
| PCT/US2016/021843 WO2016145234A2 (en) | 2015-03-12 | 2016-03-10 | Use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018512401A JP2018512401A (ja) | 2018-05-17 |
| JP2018512401A5 true JP2018512401A5 (OSRAM) | 2019-04-25 |
Family
ID=56880599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017548089A Pending JP2018512401A (ja) | 2015-03-12 | 2016-03-10 | Ｍｋ２阻害剤ペプチド含有組成物を用いた非小細胞肺癌の治療を目的とするその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9999655B2 (OSRAM) |
| EP (1) | EP3268022A4 (OSRAM) |
| JP (1) | JP2018512401A (OSRAM) |
| KR (1) | KR20170125090A (OSRAM) |
| CN (1) | CN107921082A (OSRAM) |
| AU (1) | AU2016229017A1 (OSRAM) |
| BR (1) | BR112017019343A2 (OSRAM) |
| CA (1) | CA2978941A1 (OSRAM) |
| HK (1) | HK1249433A1 (OSRAM) |
| MX (1) | MX2017011633A (OSRAM) |
| RU (1) | RU2017135072A (OSRAM) |
| SG (1) | SG11201707281QA (OSRAM) |
| WO (1) | WO2016145234A2 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10617717B2 (en) | 2016-12-04 | 2020-04-14 | Expression Pathology, Inc. | Methods of treating lung cancer by predicting responders to cisplatin-pemetrexed combination therapy |
| US11408887B2 (en) | 2017-05-22 | 2022-08-09 | The National Institute for Biotechnology in the Negev Ltd. | Biomarkers for diagnosis of lung cancer |
| US10952799B2 (en) * | 2017-05-31 | 2021-03-23 | Covidien Lp | Systems and methods for navigational bronchoscopy and selective drug delivery |
| WO2018231722A1 (en) * | 2017-06-12 | 2018-12-20 | Moerae Matrix, Inc. | Immunomodulatory effect of inhaled kinase inhibitor peptides in lung |
| WO2019238738A1 (en) * | 2018-06-12 | 2019-12-19 | Universite De Geneve | Peptidic protein kinase c inhibitors and uses thereof |
| US11195062B2 (en) | 2018-11-15 | 2021-12-07 | Nantomics, Llc | Classification based on characterization analysis methods and systems |
| WO2021019526A1 (en) | 2019-07-29 | 2021-02-04 | Yeda Research And Development Co. Ltd. | Methods of treating and diagnosing lung cancer |
| CN113261532A (zh) * | 2020-02-17 | 2021-08-17 | 中山大学 | 一种肺癌动物模型的构建方法 |
| EP4114411A4 (en) * | 2020-03-02 | 2024-04-24 | Washington University | Compositions and methods for the treatment of pancreatic cancer |
| US20220151920A1 (en) * | 2020-11-18 | 2022-05-19 | Bend Research, Inc. | Inhalable dry powder formulations comprising angiogenesis inhibitors |
| WO2023134764A1 (zh) | 2022-01-14 | 2023-07-20 | 上海翰森生物医药科技有限公司 | 含吡啶多环类衍生物、其制备方法和应用 |
| CN120390642A (zh) * | 2022-10-27 | 2025-07-29 | 百时美施贵宝公司 | Mk2抑制剂及其用途 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1521000A (en) | 1975-06-13 | 1978-08-09 | Syntex Puerto Rico Inc | Inhalation device |
| US4227522A (en) | 1978-09-05 | 1980-10-14 | Syntex Puerto Rico, Inc. | Inhalation device |
| US4192309A (en) | 1978-09-05 | 1980-03-11 | Syntex Puerto Rico, Inc. | Inhalation device with capsule opener |
| US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
| NL192564C (nl) | 1982-10-08 | 1997-10-03 | Glaxo Group Ltd | Inrichting voor het toedienen van medicamenten aan patiënten. |
| EP0211595B1 (en) | 1985-07-30 | 1991-11-13 | Glaxo Group Limited | Devices for administering medicaments to patients |
| JPH05963A (ja) | 1990-04-13 | 1993-01-08 | Toray Ind Inc | ポリペプチド類組成物 |
| US6331318B1 (en) | 1994-09-30 | 2001-12-18 | Emisphere Technologies Inc. | Carbon-substituted diketopiperazine delivery systems |
| US5352461A (en) | 1992-03-11 | 1994-10-04 | Pharmaceutical Discovery Corporation | Self assembling diketopiperazine drug delivery system |
| AU4115693A (en) | 1992-04-24 | 1993-11-29 | Sri International | In vivo homologous sequence targeting in eukaryotic cells |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| CN1048254C (zh) | 1993-12-09 | 2000-01-12 | 托马斯杰弗逊大学 | 用于将预定的改变引入靶基因中的化合物 |
| US6428771B1 (en) | 1995-05-15 | 2002-08-06 | Pharmaceutical Discovery Corporation | Method for drug delivery to the pulmonary system |
| CA2367131C (en) | 1999-04-05 | 2007-07-03 | Solomon S. Steiner | Methods for fine powder formation |
| EP2280004B1 (en) | 1999-06-29 | 2016-04-20 | MannKind Corporation | Pharmaceutical formulations comprising insulin complexed with a diketopiperazine |
| US8853266B2 (en) * | 2001-12-06 | 2014-10-07 | University Of Tennessee Research Foundation | Selective androgen receptor modulators for treating diabetes |
| US20060039985A1 (en) | 2004-04-27 | 2006-02-23 | Bennett David B | Methotrexate compositions |
| DK1786784T3 (da) | 2004-08-20 | 2011-02-14 | Mannkind Corp | Katalyse af diketopiperazinsyntese |
| CN104436170B (zh) | 2004-08-23 | 2018-02-23 | 曼金德公司 | 用于药物输送的二酮哌嗪盐 |
| KR20070057829A (ko) | 2004-08-23 | 2007-06-07 | 맨카인드 코포레이션 | 포스포디에스테라아제 5형의 억제제의 폐 전달 |
| AU2006290227B2 (en) | 2005-09-14 | 2012-08-02 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
| KR20080096809A (ko) | 2006-02-22 | 2008-11-03 | 맨카인드 코포레이션 | 디케토피페라진 및 활성제를 포함하는 마이크로입자의 약학특성의 개선 방법 |
| DK2155228T3 (da) * | 2007-01-10 | 2014-07-07 | Purdue Research Foundation | Polypeptidinhibitorer af HSP27-kinase og anvendelser herfor |
| JP5703466B2 (ja) * | 2007-08-07 | 2015-04-22 | パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ | キナーゼ阻害薬およびその使用 |
| KR20170001756A (ko) | 2008-10-20 | 2017-01-04 | 모레 매트릭스 인코포레이티드 | 유착 치료 또는 예방용 폴리펩티드 |
| AU2009324661A1 (en) | 2008-12-10 | 2011-07-07 | Purdue Research Foundation | Cell-permeant peptide-based inhibitor of kinases |
| WO2011017132A2 (en) | 2009-07-27 | 2011-02-10 | Purdue Research, Foundation | Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration |
| US20130115256A1 (en) | 2010-05-24 | 2013-05-09 | Cynthia Lander | Methods for treating or preventing vascular graft failure |
| US10105356B2 (en) * | 2011-01-31 | 2018-10-23 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| US9890200B2 (en) * | 2011-04-12 | 2018-02-13 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| SG194135A1 (en) * | 2011-04-12 | 2013-11-29 | Matrix Inc Moerae | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| BR112014030750A2 (pt) | 2012-06-06 | 2017-08-22 | Inst Catalana Recerca Estudis Avancats | Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar |
| US20140072613A1 (en) | 2012-09-10 | 2014-03-13 | Cynthia Lander | Compositions and Methods for Treating Cutaneous Scarring |
-
2016
- 2016-03-10 RU RU2017135072A patent/RU2017135072A/ru not_active Application Discontinuation
- 2016-03-10 US US15/066,976 patent/US9999655B2/en not_active Expired - Fee Related
- 2016-03-10 MX MX2017011633A patent/MX2017011633A/es unknown
- 2016-03-10 JP JP2017548089A patent/JP2018512401A/ja active Pending
- 2016-03-10 CN CN201680022723.9A patent/CN107921082A/zh active Pending
- 2016-03-10 HK HK18109079.5A patent/HK1249433A1/zh unknown
- 2016-03-10 CA CA2978941A patent/CA2978941A1/en not_active Abandoned
- 2016-03-10 KR KR1020177028070A patent/KR20170125090A/ko not_active Withdrawn
- 2016-03-10 AU AU2016229017A patent/AU2016229017A1/en not_active Abandoned
- 2016-03-10 SG SG11201707281QA patent/SG11201707281QA/en unknown
- 2016-03-10 WO PCT/US2016/021843 patent/WO2016145234A2/en not_active Ceased
- 2016-03-10 BR BR112017019343A patent/BR112017019343A2/pt not_active Application Discontinuation
- 2016-03-10 EP EP16762545.8A patent/EP3268022A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017135072A (ru) | Применение пептидсодержащих композиций ингибитора mk2 для лечения немелкоклеточного рака легкого | |
| JP6685875B2 (ja) | 治療薬の組み合わせおよび投与の様式ならびに併用療法 | |
| TWI599369B (zh) | 包含阿柏西普（ａｆｌｉｂｅｒｃｅｐｔ）、醛葉酸、５－氟尿嘧啶（５－ｆｕ）及伊立替康（ｉｒｉｎｏｔｅｃａｎ）（ｆｏｌｆｉｒｉ）之組合物 | |
| Zarogoulidis et al. | Feasibility and effectiveness of inhaled carboplatin in NSCLC patients | |
| JP2022031331A (ja) | 空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法 | |
| Wauthoz et al. | Inhaled cytotoxic chemotherapy: Clinical challenges, recent developments, and future prospects | |
| Fulzele et al. | Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model | |
| Paudel et al. | Targeting lung cancer using advanced drug delivery systems | |
| Chen et al. | Nab-paclitaxel (abraxane)-based chemotherapy to treat elderly patients with advanced non-small-cell lung cancer: a single center, randomized and open-label clinical trial | |
| Lee et al. | Paclitaxel-loaded polymeric micelle (230 mg/m2) and cisplatin (60 mg/m2) vs. paclitaxel (175 mg/m2) and cisplatin (60 mg/m2) in advanced Non–small-cell lung cancer: a multicenter randomized phase IIB trial | |
| Kentepozidis et al. | Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group | |
| Shih et al. | Bozitinib, a highly selective inhibitor of cMet, demonstrates robust activity in gastric, lung, hepatic and pancreatic in vivo models | |
| Wysocka et al. | Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma | |
| TW202245768A (zh) | 用於治療小細胞肺癌之氧雜雙環庚烷 | |
| Brus et al. | Second line therapy for advanced pancreatic adenocarcinoma: where are we and where are we going | |
| Hu et al. | Current status of CPT and its analogues in the treatment of malignancies | |
| Lu et al. | Effects of paclitaxel liposome and capecitabine in the treatment of advanced gastric cancer by clinical observation | |
| JP2021521130A (ja) | 増殖性障害の治療のための投薬レジメン | |
| Abdel-Ghany et al. | Titanium oxide nanoparticles improve the chemotherapeutic action of erlotinib in liver cancer cells | |
| Zia et al. | Concurrent radiotherapy and chemotherapy with erlotinib followed by maintenance erlotinib in patients with Epidermal Growth Factor Receptor mutation-positive adenocarcinoma lung | |
| AU2020356356A1 (en) | Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma | |
| KR20230038659A (ko) | 나노 입자, 전리 방사선 및 그의 혁신적인 치료용 조합 | |
| Yingchun et al. | Application of nano-drug delivery technology in overcoming drug resistance in lung cancer | |
| Park et al. | Phase II trial of weekly docetaxel and gemcitabine for previously untreated, advanced non-small cell lung cancer | |
| Shin et al. | Prospective phase II trial of a combination of fixed dose rate infusion of gemcitabine with cisplatin and UFT as a first-line treatment in patients with advanced non-small-cell lung carcinoma |